Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10 For HRT fundamentals, see our Bioidentical Hormones Explained: What They Are and How They Work in 2026 guide.
What is the Wiley Protocol?
The Wiley Protocol is a form of bioidentical hormone replacement therapy (BHRT) created by T.S. Wiley, an author and researcher who does not hold a medical degree. The protocol uses topical (transdermal) estradiol and progesterone applied in doses that rise and fall throughout the month, attempting to replicate the hormonal fluctuations of a woman in her twenties. Wiley argues that recreating these youthful patterns can reduce menopause symptoms and improve long-term health outcomes. Peptide alternatives for menopause are covered in our menopause peptide therapy article. Progesterone dosing is critical; see our Progesterone for HRT: Complete 2026 Guide to Benefits and Dosing.
The approach was popularized through Wiley's 2003 book Sex, Lies, and Menopause and later through a network of compounding pharmacies that prepare the specific formulations. A U.S. patent was granted for the dosing method in 2011.1
How does rhythmic dosing differ from standard HRT?
Standard hormone replacement therapy for menopause typically uses a fixed daily dose of estrogen, sometimes paired with a steady or cyclical dose of progestogen. The goal is symptom relief at the lowest effective dose. The Wiley Protocol takes a different approach: it prescribes doses that fluctuate on a 28-day calendar, with estradiol peaking around day 12 (mimicking the pre-ovulatory surge) and progesterone peaking around day 21 (mimicking the luteal phase). Estrogen cycling raises questions about Estrogen Dominance Explained: Causes Symptoms and Treatment.
The doses used in the Wiley Protocol are significantly higher than those in conventional HRT. Wiley has stated that the schedule and hormone levels matter more than the bioidentical nature of the hormones themselves.1 Conventional HRT, by contrast, follows established clinical guidelines from organizations like the North American Menopause Society (NAMS) and the Endocrine Society, both of which recommend the lowest effective dose for the shortest necessary duration.2
| Feature | Wiley Protocol | Standard HRT |
|---|---|---|
| Dosing pattern | Rhythmic, cycling over 28 days | Fixed daily dose (continuous or sequential) |
| Dose levels | High (mimics peak reproductive levels) | Lowest effective dose |
| Hormones used | Topical bioidentical estradiol + progesterone | Various (oral, transdermal, bioidentical or synthetic) |
| Delivery | Compounded topical creams | FDA-approved patches, pills, gels, creams |
| Clinical trial support | None (no published RCTs) | Extensive (WHI, KEEPS, ELITE trials) |
| Medical society endorsement | None | NAMS, Endocrine Society, ACOG |
What are the claimed benefits of the Wiley Protocol?
Proponents say that restoring a youthful hormonal rhythm, rather than providing a flat daily dose, better supports the body's endocrine function. The claimed benefits include relief from hot flashes, improved sleep, better libido, increased bone density, mood stabilization, and a general reversal of age-related hormonal decline. Some advocates argue that static-dose HRT fails to address the complexity of the endocrine system and that cycling doses more closely matches what the body evolved to expect.
Personalized hormone therapy for women
Work with a licensed provider to find the right hormone optimization plan for your symptoms and goals.
Start Free Assessment →These claims are based on physiological reasoning rather than clinical evidence. The idea that the body responds better to fluctuating hormone levels has biological plausibility: progesterone receptors, for example, are known to downregulate under constant stimulation.3 But plausibility is not proof, and no controlled trial has tested whether the Wiley Protocol's specific dosing schedule produces better outcomes than standard approaches.
What hormones does the Wiley Protocol use?
The protocol uses two hormones, both bioidentical (structurally identical to those produced by the human body):
- Estradiol (E2): Applied as a topical cream in doses that increase during days 1 through 12 of the cycle, peak around day 12, then taper. The peak dose is designed to approximate the estradiol surge seen before ovulation in premenopausal women.
- Progesterone (P4): Applied topically starting around day 14, increasing to a peak around day 21, then tapering off by day 28. This mimics the luteal phase pattern of progesterone production by the corpus luteum.
Both hormones are prepared by compounding pharmacies registered with the Wiley Protocol network. The specific formulations and bases used can vary between pharmacies, which has been a point of concern for critics who note that compounded preparations lack the batch-to-batch consistency of FDA-approved products.4
Why is the Wiley Protocol controversial?
The controversy around the Wiley Protocol comes from multiple directions. The most fundamental concern is the absence of randomized controlled trial data. No peer-reviewed study has demonstrated that this specific dosing regimen is safe or effective for any indication.
In 2006, seven physicians (including several menopause specialists) published an open letter calling the protocol "scientifically unproven and dangerous." Their objections included the supraphysiologic doses used, Wiley's lack of medical training, and the absence of standard safety monitoring.1
A 2008 analysis in Menopause journal cataloged the ethical problems with the protocol. The authors found failures in informed consent, investigator expertise, methodology, standardized data collection, and data safety monitoring. They also identified conflicts of interest related to financial incentives in the pharmacy network.1
Mainstream OB/GYNs and endocrinologists generally reject the protocol. The American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society have both issued position statements warning against unregulated compounded hormone preparations, particularly those marketed with claims not supported by clinical data.5
What are the risks of high-dose rhythmic hormone therapy?
The Women's Health Initiative (WHI) established that even standard-dose estrogen-progestogen therapy carries risks including blood clots, stroke, and breast cancer with long-term use.6 The Wiley Protocol uses higher doses than those studied in WHI, which raises concern that the risks could be proportionally greater.
Specific concerns include:
- Endometrial stimulation from high estradiol doses, potentially increasing the risk of endometrial hyperplasia or cancer if progesterone opposition is insufficient
- Breast tissue stimulation from supraphysiologic estradiol levels
- Thromboembolism risk, though transdermal delivery generally carries lower clot risk than oral estrogen
- Side effects reported by protocol users, including breakthrough bleeding, breast tenderness, bloating, and mood swings
- Unreliable serum monitoring, since transdermal hormones are poorly reflected in standard blood tests
Some women have stopped the protocol due to side effects. Without systematic adverse event tracking, the true incidence of problems is unknown.1
Who is T.S. Wiley?
T.S. Wiley holds no medical degree, nursing license, or pharmacy credential. She describes herself as a medical researcher and anthropologist. Her background is in writing: she has published several books on hormones, sleep, and evolutionary biology. The protocol bears her name and she has maintained control over its formulation standards and pharmacy network.
This matters because the protocol functions as a clinical intervention prescribed to patients, yet its designer cannot legally practice medicine, prescribe drugs, or oversee clinical trials. Physicians who prescribe the Wiley Protocol do so under their own medical licenses, but the formulations and dosing schedules originate from someone without clinical training. The 2008 ethical analysis characterized this as a failure of professional ethics standards.1
Should you consider the Wiley Protocol?
If you are experiencing menopause symptoms and considering hormone therapy, the evidence supports starting with FDA-approved options that have been studied in large clinical trials. Bioidentical hormones are available in FDA-approved formulations (such as estradiol patches and micronized progesterone capsules) that provide the same molecular hormones as compounded products, with the added assurance of standardized manufacturing and regulatory oversight.
The concept of rhythmic dosing is intellectually interesting, and it is possible that future research will validate some version of cyclical hormone delivery. But at present, no data supports choosing the Wiley Protocol over evidence-based alternatives. Any decision about hormone replacement therapy should involve a thorough discussion with a qualified healthcare provider about your personal risk factors, symptoms, and goals.
Frequently Asked Questions
Is the Wiley Protocol FDA-approved?
No. The Wiley Protocol has never been submitted to or approved by the FDA. The compounded hormones used in the protocol are also not FDA-approved products, though the individual active ingredients (estradiol and progesterone) are available in FDA-approved formulations from other manufacturers.
Are bioidentical hormones safer than synthetic hormones?
The Endocrine Society and NAMS have stated that bioidentical hormones are not inherently safer than their synthetic counterparts. The term "bioidentical" refers to molecular structure, not safety profile. FDA-approved bioidentical options (like Estrace and Prometrium) have the same safety and efficacy data as any other approved medication.
What does "rhythmic dosing" mean in hormone therapy?
Rhythmic dosing means the hormone dose changes throughout the month rather than staying constant. The Wiley Protocol adjusts estradiol and progesterone doses on a 28-day cycle to approximate the hormonal fluctuations of a premenopausal menstrual cycle. Standard HRT uses either continuous fixed dosing or a simpler sequential pattern.
Has the Wiley Protocol been studied in clinical trials?
No randomized controlled trials of the Wiley Protocol have been published in peer-reviewed medical journals. An observational study was reportedly conducted through the protocol's pharmacy network, but it lacked standard research protections including IRB oversight, informed consent procedures, and independent data monitoring.
Can my regular doctor prescribe the Wiley Protocol?
Any licensed physician can prescribe compounded hormones, including the Wiley Protocol formulations. However, most mainstream gynecologists and endocrinologists do not recommend the protocol due to the lack of supporting clinical evidence and concerns about the high doses used. If you are interested in bioidentical hormones, your doctor can prescribe FDA-approved bioidentical options.
What are the side effects of the Wiley Protocol?
Reported side effects include breakthrough bleeding, breast tenderness, bloating, headaches, and mood changes. Because the doses used are higher than standard HRT, some women experience more pronounced side effects. Without systematic tracking, the full side effect profile is not well characterized.
Are compounded hormones regulated?
Compounding pharmacies are regulated at the state level and, in some cases, by the FDA under the Drug Quality and Security Act (2013). However, compounded preparations are not subject to the same pre-market approval, batch testing, and labeling requirements as commercially manufactured FDA-approved drugs. This gap in regulation has been a central concern in the debate over protocols like the Wiley Protocol.
Is there a safer alternative to the Wiley Protocol for bioidentical HRT?
Yes. FDA-approved bioidentical hormones include estradiol patches (Climara, Vivelle-Dot), estradiol gel (EstroGel), and micronized progesterone (Prometrium). These products use the same bioidentical molecules as the Wiley Protocol but are manufactured under strict FDA quality controls and have been studied in clinical trials. Talk to your provider about bioidentical hormone options.
Medical References
- Cirigliano M. "The Wiley Protocol: an analysis of ethical issues." Menopause. 2008;15(5):1014-1022. PMID: 18551081
- The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. "The 2017 hormone therapy position statement of The North American Menopause Society." Menopause. 2017;24(7):728-753. PMID: 28763535
- Vegeto E, et al. "The role of progesterone receptor in health and disease." Front Biosci. 2005;10:2124-2136. PMID: 15635504
- Boothby LA, Doering PL. "Ethical problems with bioidentical hormone therapy." Int J Impot Res. 2008;20(1):45-52. PMID: 18075509
- ACOG Committee Opinion No. 532. "Compounded bioidentical menopausal hormone therapy." Obstet Gynecol. 2012;120(2 Pt 1):411-415. Reaffirmed 2017. PMID: 29028024
- Rossouw JE, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial." JAMA. 2002;288(3):321-333. PMID: 12117397
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
FDA: unapproved GLP-1 drug safety concerns
RegulatorUsed for safety language around compounded, counterfeit, and unapproved GLP-1 products.
ADA Standards of Care in Diabetes 2026
GuidelineUsed for diabetes, cardiometabolic risk, and obesity-treatment context.
STEP 1 semaglutide obesity trial
TrialPrimary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.
SURMOUNT-1 tirzepatide obesity trial
TrialPrimary trial source for tirzepatide weight-loss expectations and dose-response ranges.
PubMed evidence trail
Research sources used to frame this page
For The Wiley Protocol: What Is Rhythmic Bioidentical Hormone Dosing?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Management of menopause: a view towards prevention
Used for broad prevention and risk-benefit context in hormone-related pages.
PubMed
Hormone decision path
Use the page to prepare for a monitored care conversation
Direct answer
The Wiley Protocol: What Is Rhythmic Bioidentical Hormone Dosing? is a clinical decision, not a generic supplement choice. Symptoms, labs, history, medication use, fertility goals, and follow-up monitoring all matter.
Evidence check
The best next read should connect symptoms and outcomes to labs, safety monitoring, and real provider decision points.
Safety check
Hormone therapy requires licensed review because dosing, contraindications, fertility, mood, cardiovascular risk, and follow-up labs can change the plan.
Next step
Continue into the get-started flow when you want a provider to evaluate whether this path fits your situation.
FormBlends Editorial Context
Reviewed May 14, 2026The Wiley Protocol uses cycling doses of bioidentical estradiol and progesterone to mimic the natural menstrual cycle. This guide covers how it works, how it differs from standard HRT, the controversy around it, and what the evidence says. "The Wiley Protocol: What Is Rhythmic Bioidentical Hormone Dosing?" works best as a practical checklist for the next conversation. It focuses on dosing literacy and clinician follow-up, then narrows the issue through hormone therapy, dosing. With 7 sections, the FAQ can reveal what readers usually miss. Use the page to prepare, then verify the personal medical pieces with a licensed clinician.
- Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
- Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
- Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for The Wiley Protocol
This update makes The Wiley Protocol more specific by tying hormone therapy, safety signals, wiley, protocol, bioidentical, hormones to the page's original clinical, cost, access, or comparison angle.
The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable women's health summary.
For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.
Custom 2026 image for The Wiley Protocol, women's health, and better treatment decision-making.
Download the Women\u2019s Hormone Optimization Guide
A printable guide covering HRT options, symptom tracking, and questions to ask your provider.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by FormBlends Editorial Research
Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.